OREON Life Science: A K-Medical Aesthetic Specialist
Driven by Sincerity and Technologyย
โWe will become a medical aesthetic specialist that improves the quality of human life by adding sincerity to technology.โ
Founded in 2008, OREON Life Science (CEO Jeong-hoon Oh) has targeted the medical aesthetic market in the field of anti-aging, striving to leap forward as a global aesthetic group.
Notably, OREON Life Science has established a cooperative network in approximately 80 countries worldwide to supply its products. Recently, the company has recorded an average growth rate of 31% over the past five years and an operating profit margin of 33.2%.
From the product development stage, OREON Life Science prioritizes production efficiency and consistency. Specialists from the manufacturing sector participate directly to review production feasibility and process optimization in advance. Automated equipment has been introduced in major manufacturing processes to minimize human error and ensure stable production volumes. The automation of the packaging process using collaborative robots simultaneously satisfies mass production needs and quality consistency. By linking this production environment from the development stage, the company maintains high quality standards even after the commercialization of its products.
In addition, OREON Life Science manages the entire development and production process based on quality control standards equivalent to those of pharmaceutical companies. By operating a dedicated quality control team and conducting thorough inspections using analytical equipment, the company has minimized the defect rate for both semi-finished and finished products. Through an incoming inspection system, the influx of defective raw materials is blocked in advance, and a supplier evaluation system is operated to manage product quality from the raw material stage.
The flagship product, โiLEAD HA Filler,โ features high-purity hyaluronic acid that has undergone multi-stage purification to lower endotoxin levels to 0.025 EU. Applying the latest cross-linking technology, it boasts excellent volume retention and durability, while containing 24mg of cross-linked HA to provide viscoelasticity and lifting effects. The โiLEADโ series consists of the โiLEAD 70mLโโa large-capacity product exclusive for the bodyโand specialized lines for each treatment area: โฒGLOBAL, โฒDEEP, โฒULTRA, and โฒX. Among these, โiLEAD 70mLโ is gaining high industry interest as an optimized product for body contouring and volume enhancement through its large-capacity format. โGLOBALโ is suitable for shallow areas such as frown lines and brow wrinkles, as well as for treatments around the eyes and lip contours. โDEEPโ is effective for lip volume, nasolabial folds, marionette lines, and contour improvement of the forehead and bridge of the nose. โULTRAโ is used extensively for forehead volume, deep wrinkles, jawlines, and body contouring, with long-term durability of over 12 months. โXโ is a high-viscoelasticity body filler designed for body correction in areas like the hips and chest, providing strong lifting power and shape retention. Each product is engineered with differentiated viscoelasticity and particle size depending on the treatment area to respond precisely to various clinical purposes.
Furthermore, โiยทNOVAโ is a skin rejuvenator product that blends high and low-molecular weight HA in an optimal ratio. it includes key ingredients that support skin regeneration, such as amino acid complexes, ascorbyl glucoside, succinic acid, and niacinamide. It offers complex effects including hydration, elasticity, whitening, and antioxidants, and is used in various treatments requiring skin condition improvement.
In particular, OREON Life Science has strengthened its product competitiveness and corporate reliability by being certified as a โPromising Small and Medium Enterprise of Gyeonggi-doโ by Gyeonggi Province and the Gyeonggi Business & Science Accelerator.
CEO Jeong-hoon Oh stated, โOreonโs core product lines have obtained numerous global medical device and cosmetic certifications, including CE certification and CPNP registration, earning recognition for their outstanding safety and efficacy in overseas markets, including Europe.โ He added, โWe plan to solidify our position as a K-medical brand that symbolizes trust and innovation in the global market.โ
๐ https://www.kyeonggi.com/article/20250917580138ย
OREON Life Science: A K-Medical Aesthetic Specialist
Driven by Sincerity and Technologyย
โWe will become a medical aesthetic specialist that improves the quality of human life by adding sincerity to technology.โ
Founded in 2008, OREON Life Science (CEO Jeong-hoon Oh) has targeted the medical aesthetic market in the field of anti-aging, striving to leap forward as a global aesthetic group.
Notably, OREON Life Science has established a cooperative network in approximately 80 countries worldwide to supply its products. Recently, the company has recorded an average growth rate of 31% over the past five years and an operating profit margin of 33.2%.
From the product development stage, OREON Life Science prioritizes production efficiency and consistency. Specialists from the manufacturing sector participate directly to review production feasibility and process optimization in advance. Automated equipment has been introduced in major manufacturing processes to minimize human error and ensure stable production volumes. The automation of the packaging process using collaborative robots simultaneously satisfies mass production needs and quality consistency. By linking this production environment from the development stage, the company maintains high quality standards even after the commercialization of its products.
In addition, OREON Life Science manages the entire development and production process based on quality control standards equivalent to those of pharmaceutical companies. By operating a dedicated quality control team and conducting thorough inspections using analytical equipment, the company has minimized the defect rate for both semi-finished and finished products. Through an incoming inspection system, the influx of defective raw materials is blocked in advance, and a supplier evaluation system is operated to manage product quality from the raw material stage.
The flagship product, โiLEAD HA Filler,โ features high-purity hyaluronic acid that has undergone multi-stage purification to lower endotoxin levels to 0.025 EU. Applying the latest cross-linking technology, it boasts excellent volume retention and durability, while containing 24mg of cross-linked HA to provide viscoelasticity and lifting effects. The โiLEADโ series consists of the โiLEAD 70mLโโa large-capacity product exclusive for the bodyโand specialized lines for each treatment area: โฒGLOBAL, โฒDEEP, โฒULTRA, and โฒX. Among these, โiLEAD 70mLโ is gaining high industry interest as an optimized product for body contouring and volume enhancement through its large-capacity format. โGLOBALโ is suitable for shallow areas such as frown lines and brow wrinkles, as well as for treatments around the eyes and lip contours. โDEEPโ is effective for lip volume, nasolabial folds, marionette lines, and contour improvement of the forehead and bridge of the nose. โULTRAโ is used extensively for forehead volume, deep wrinkles, jawlines, and body contouring, with long-term durability of over 12 months. โXโ is a high-viscoelasticity body filler designed for body correction in areas like the hips and chest, providing strong lifting power and shape retention. Each product is engineered with differentiated viscoelasticity and particle size depending on the treatment area to respond precisely to various clinical purposes.
Furthermore, โiยทNOVAโ is a skin rejuvenator product that blends high and low-molecular weight HA in an optimal ratio. it includes key ingredients that support skin regeneration, such as amino acid complexes, ascorbyl glucoside, succinic acid, and niacinamide. It offers complex effects including hydration, elasticity, whitening, and antioxidants, and is used in various treatments requiring skin condition improvement.
In particular, OREON Life Science has strengthened its product competitiveness and corporate reliability by being certified as a โPromising Small and Medium Enterprise of Gyeonggi-doโ by Gyeonggi Province and the Gyeonggi Business & Science Accelerator.
CEO Jeong-hoon Oh stated, โOreonโs core product lines have obtained numerous global medical device and cosmetic certifications, including CE certification and CPNP registration, earning recognition for their outstanding safety and efficacy in overseas markets, including Europe.โ He added, โWe plan to solidify our position as a K-medical brand that symbolizes trust and innovation in the global market.โ
๐ https://www.kyeonggi.com/article/20250917580138ย